Clinical trials: HIV Infected Individuals
Human Immunodeficiency Virus (HIV) Infection
Folinic Acid and Vascular Reactivity in HIV
Objective: HIV infected individuals present a cluster of conditions that activate or injure the vascular endothelium. The administration of folates may exert beneficial effects on endothelial function in different populations at…
- Trial name
- NCT01768182
- Testing
- Folinic Acid
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
HIV
Impact of a Short-Term Analytical Treatment Interruption and Re-Initiation of Antiretroviral Therapy on Immunologic and Virologic Parameters in HIV-Infected Individuals
Background: The immune system helps the body fight off disease. Most people infected with HIV cannot control the infection and need daily medicine.
- Trial name
- NCT03225118
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Human Immunodeficiency Virus Type I Infection
Feasibility of Identifying, Enrolling and Following Acute and Early HIV-1 Infected Individuals.
It is only between peak viremia and viral setpoint in natural acute HIV-1 infection that the immune response overwhelms viral replication resulting in a plasma viral load decline.
- Trial name
- KILGORIS (NCT05372510)
- Where
- Uganda
- Volunteers
- 100 people
- Sponsor
- MRC/UVRI and LSHTM Uganda Research Unit
HIV
Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals
An Exploratory Multicenter, Open-label, Sequential Cohort Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacokinetic Characteristics of LP-98 for Injection in Antiretroviral Therapy-Naive HIV-Infected Individuals
- Trial name
- NCT07433387
- Testing
- LP-98 20 mg, LP-98 40 mg, LP-98 80 mg
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanxi Kangbao Biological Product Co., Ltd.
HIV Infections
Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity
To determine the minimal effective (immunogenic) dose of vaccine in asymptomatic HIV-1 seropositive individuals with > 400 cells/mm3 (CD4). To determine the dose-response to a 4 fold escalation of the immunizing dose.
- Trial name
- NCT00000977
- Testing
- gp160 Vaccine (MicroGeneSys)
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Monitoring, Immunologic, Active Tuberculosis
New Generation IGRA in Immunocompromised Individuals
Evaluation of a new ELISA based interferon-gamma release assay (QuantiFERON TB plus In-tube test) in immunocompromized patients
- Conditions
- Monitoring, Immunologic, Active Tuberculosis, Tuberculosis in Solid Organ Transplant Recipients, Tuberculosis in Marrow Transplant Recipients
- Trial name
- TBnet#54 (NCT02639936)
- Where
- 16 sites in Denmark, Germany and 8 more
- Volunteers
- 2,663 people, healthy volunteers welcome
- Sponsor
- Tuberculosis Network European Trialsgroup
HIV-Infected Individuals
Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)
This is a multi-site phase 1 study of the safety, immunologic and virologic responses of ex vivo expanded donor-derived (DD) HIV-1 multi-antigen specific T-cell (HST) with non-escaped epitope targeting (NEET) therapy as a…
- Trial name
- NCT04248192
- Testing
- DD HST-NEETs
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Catherine Bollard
HIV Infections
Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to give combinations of three or four anti-HIV drugs to HIV-infected patients.
- Trial name
- NCT00002211
- Testing
- Nelfinavir mesylate, Delavirdine mesylate, Stavudine
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Pharmacia and Upjohn
HIV-1 Infection
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
Since people started taking HIV medications, illnesses related to AIDS have decreased, but other serious illnesses like heart disease (heart attacks) and certain kinds of cancer have increased.
- Trial name
- NCT01515813
- Testing
- Pravastatin sodium, Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
- Where
- 9 sites in United States
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infections
Optimisation of Care in Vulnerable HIV Infected Individuals
Antiretroviral therapy is currently the only way to control HIV disease progression in HIV infected subjects and to prevent transmission.
- Trial name
- OPTICARE (NCT03799276)
- Testing
- Opticare study
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
HIV Infections
A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks
The purpose of this study is to compare different treatments for HIV infection to see which works best to lower HIV levels and to raise the number of CD4 cells (cells of the immune system that fight infection), in HIV-positive…
- Trial name
- NCT00000914
- Testing
- Indinavir sulfate, Ritonavir, Nelfinavir mesylate
- Where
- 15 sites in United States
- Volunteers
- 800 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients
The purpose of this study is to determine if two dose levels of indinavir combined with two nucleoside analogue reverse transcriptase inhibitors (NRTIs) have the same effect on plasma viral load (level of HIV in the blood).
- Trial name
- NCT00002406
- Testing
- Indinavir sulfate
- Where
- 29 sites in United States
- Volunteers
- 350 people
- Sponsor
- Merck Sharp & Dohme LLC
Cytomegalovirus Retinitis, HIV Infections
The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV
To evaluate the safety and efficacy of oral ganciclovir for prophylaxis against cytomegalovirus (CMV) retinal and gastrointestinal mucosal disease in HIV-infected patients with severe immunosuppression.
- Conditions
- Cytomegalovirus Retinitis, HIV Infections, Gastrointestinal Diseases
- Trial name
- NCT00001034
- Testing
- Ganciclovir
- Where
- 17 sites in United States
- Volunteers
- 850 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
MARCH Central Nervous System Substudy
This substudy is a prospective, observational, open-label, randomised study within the MARCH study. The purpose of this substudy is to investigate the changes in cerebral function parameters at 5 timepoints over 96 weeks of the…
- Trial name
- NCT01637233
- Testing
- Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors, Arm 2 Maraviroc and Protease Inhibitors, Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors
- Where
- 6 sites in Argentina, Thailand and 1 more
- Volunteers
- 28 people
- Sponsor
- Kirby Institute
HIV
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
The purpose of this study is to determine the proportion of subjects with HIV-1 RNA < 50 c/mL at Week 48 in patients who failed their first line therapy containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) or an…
- Trial name
- SUPPRESS (NCT01605084)
- Testing
- Atazanavir, Darunavir, Ritonavir
- Where
- 14 sites in United States
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
HIV is characterized by frequent immune system activation. Early in the course of infection the body establishes an immune activation "set point" related to the amount of HIV in the blood stream.
- Trial name
- NCT00819390
- Testing
- Chloroquine
- Where
- 15 sites in United States
- Volunteers
- 70 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Human Immunodeficiency Virus, Growth Hormone Treatment
Impact of Recombinant Human Growth Hormone on HIV Persistence
Antiretroviral therapy (ART) has improved the health of more than 18 million people infected with HIV by controlling viral replication, AIDS and non-AIDS events, and by reducing the risk of transmission.
- Trial name
- NCT03091374
- Testing
- Somatotropin (Human)
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
HIV Seropositivity, Kaposi's Sarcoma
Effects of Potent Antiretroviral Therapy on Kaposi s Sarcoma
Background: Kaposi s sarcoma (KS) is caused by a gammaherpesvirus called Kaposi s sarcoma-associated herpesvirus (KSHV), or human herpesvirus-8 (HHV-8).
- Conditions
- HIV Seropositivity, Kaposi's Sarcoma, HIV Infections
- Trial name
- NCT00006171
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
Adherence to Antiretroviral Therapy in HIV Infected Individuals in Assiut Governorate, Egypt
Egypt is a HIV low prevalence country but between 2010 and 2019 newly infected cases have more than quadrupled, and the rise continues at an alarming pace.
- Trial name
- NCT05953844
- Volunteers
- 278 people
- Sponsor
- Assiut University
HIV Infections
HIV and Changes in the Gut Microbiome After Changes in Antiretroviral Therapy (ART)
This is a study that aims to contribute to the understanding of how antiretroviral therapy effects the gut microbiome which, if known, could inform decisions about drug choices at an individual level.
- Trial name
- NCT06100211
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- University of Manchester